ArticleExperimental & molecular medicine2024

Immunoliposome-based targeted delivery of the CRISPR/Cas9gRNA-IL30 complex inhibits prostate cancer and prolongs survival.

Cristiano Fieni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.